Nouhad Husseini
Director/Board Member presso DECIBEL THERAPEUTICS, INC.
Posizioni attive di Nouhad Husseini
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2011 | - |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 31/05/2022 | - |
| Corporate Officer/Principal | 31/05/2022 | - | |
| DECIBEL THERAPEUTICS, INC. | Director/Board Member | 22/09/2023 | - |
| Corporate Officer/Principal | 22/09/2023 | - |
Storia della carriera di Nouhad Husseini
Formazione di Nouhad Husseini
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Nouhad Husseini
- Esperienza
